Next Generation Tissue Biomarkers Market Report 2026

Next Generation Tissue Biomarkers Market Overview

• Next Generation Tissue Biomarkers market size has reached to $3.03 billion in 2025 • Expected to grow to $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Rising Demand For Personalized Medicine Driving Growth In The Market Due To Advancements In Genomic Technologies And Increasing FDA Approvals • Market Trend: Advancements In Genomic Technologies Enhancing Precision And Efficiency In Cancer Diagnostics And Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next Generation Tissue Biomarkers Market?

Next generation tissue biomarkers are advanced biological indicators obtained from tissue samples that allow for more detailed and accurate analysis of biological conditions. They reflect subtle molecular and cellular changes within tissues, helping to better understand various physiological and pathological processes. These biomarkers are identified through refined analytical approaches that enable a deeper examination of tissue characteristics. The main types of next generation tissue biomarkers are genomic biomarkers, proteomic biomarkers, epigenetic biomarkers, transcriptomic biomarkers, and metabolomic biomarkers. Genomic biomarkers are deoxyribonucleic acid- or ribonucleic acid-based indicators used to detect, diagnose, or predict disease risk and treatment response by analyzing genetic mutations or expression patterns. The technologies supporting these biomarkers include immunohistochemistry, next-generation sequencing, mass spectrometry-based proteomics, spatial biology platforms, digital pathology integrated with artificial intelligence, and others. The biomarkers are applied across areas such as oncology, companion diagnostics, drug discovery and development, neurology, and others, and are utilized by end users including hospitals and reference laboratories, pharmaceutical and biotechnology firms, academic and research institutes, and contract research organizations.

What Is The Next Generation Tissue Biomarkers Market Growth Forecast?

The next generation tissue biomarkers market size is expected to see rapid growth in the next few years. It will grow to $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to advancements in next-generation sequencing technologies, integration of ai-based tissue analysis, expansion of spatial biology platforms, rising investment in multi-omics research, increased collaborations between pharma and academic institutes. Major trends in the forecast period include expansion of spatial biology and multi-omics approaches, increased adoption of digital pathology and ai analysis in diagnostics, rising demand for biomarkers in oncology and companion diagnostics, growth in drug discovery and development using tissue biomarkers, integration of transcriptomic and metabolomic biomarkers for precision medicine.

Global Next Generation Tissue Biomarkers Market Segmentation

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers 2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies 3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications 4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations Subsegments: 1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions 2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions 3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation 4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants 5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

What Is The Driver Of The Next Generation Tissue Biomarkers Market?

The rising demand for personalized medicine is expected to propel the growth of the next generation tissue biomarkers market going forward. Personalized medicine is a medical approach that tailors treatment based on an individual's genetic makeup, lifestyle, and environmental factors. The adoption of personalized medicine is increasing due to continuous advancements in genomic technologies, as they allow for highly specific and individualized treatment strategies. The demand for personalized medicine is boosting the development of next-generation tissue biomarkers, as they provide precise and individualized information needed to tailor treatments to each patient's unique tissue profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is driving the growth of the next generation tissue biomarkers industry.

Key Players In The Global Next Generation Tissue Biomarkers Market

Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., Biofidelity Ltd.

Global Next Generation Tissue Biomarkers Market Trends and Insights

Major companies operating in the next generation tissue biomarkers market are focusing on developing advanced solutions, such as genomic-based diagnostic assays and sequencing solutions, to enhance the accuracy, speed, and personalization of cancer diagnosis and treatment. Genomic-based diagnostic assays and sequencing solutions refer to tools and techniques that examine genetic information to identify disease-related biomarkers, enabling more precise and personalized approaches to diagnosis and therapy. For instance, in August 2024, Illumina Inc., a US-based biotechnology company, received FDA approval for its TruSight Oncology Comprehensive test, along with two companion diagnostics, to rapidly match cancer patients to targeted therapies. The test profiles over 500 genes from a single tissue sample, enabling precise treatment selection for various solid tumors. It automates biomarker detection and supports 24/7 deployment, significantly reducing turnaround times and enhancing clinical efficiency, representing a modern approach to streamlining cancer diagnostics within a regulated framework.

What Are Latest Mergers And Acquisitions In The Next Generation Tissue Biomarkers Market?

In July 2025, Quanterix Corporation, a US-based life sciences company, acquired Akoya Biosciences Inc. for an undisclosed amount. With this acquisition, Quanterix Corporation aims to integrate Akoya’s spatial biology capabilities into its existing blood-based biomarker platform, thereby enhancing its technological depth and bolstering its position in tissue-to-blood precision diagnostics. Akoya Biosciences Inc. is a US-based life sciences technology company that provides solutions for analyzing next generation tissue biomarkers.

Regional Insights

North America was the largest region in the next generation tissue biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next Generation Tissue Biomarkers Market?

The next generation tissue biomarkers market consists of revenues earned by entities by providing services such as epigenomics analysis, single-cell analysis, and multiplex immunofluorescence. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation tissue biomarkers market also includes sales of diagnostic assays, reagents and antibodies, sequencing kits, imaging and staining systems, multiplex analysis platforms, and spatial biology instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Next Generation Tissue Biomarkers Market Report 2026?

The next generation tissue biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next generation tissue biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.